Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF
Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti-VEGF) is the first-line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns. In pseudophakic eyes with suboptimal response to first-line therapy, intravitreal cort...
Saved in:
| Main Authors: | Di Zou, Imran Jawaid, Winfried M. Amoaku |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2021/9967831 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world outcomes of early and deferred anti-VEGF treatment in diabetic macular oedema in patients with type 1 diabetes
by: Joonas Wirkkala, et al.
Published: (2025-12-01) -
Postoperative, or pseudophakic, macular edema
by: I. E. Ioshin
Published: (2020-12-01) -
Impact of anti-VEGF treatment for diabetic macular oedema on progression to proliferative diabetic retinopathy: data-driven insights from a multicentre study
by: Usha Chakravarthy, et al.
Published: (2025-07-01) -
Macular oedema as manifestation of diabetic retinopathy
by: Mukharram M. Bikbov, et al.
Published: (2017-10-01) -
Anti-VEGF for the Management of Diabetic Macular Edema
by: Francisco Rosa Stefanini, et al.
Published: (2014-01-01)